PODD logo

PODD
Insulet Corporation

1,941
Mkt Cap
$11.87B
Volume
1.47M
52W High
$354.88
52W Low
$158.35
PE Ratio
47.86
PODD Fundamentals
Price
$167.53
Prev Close
$171.39
Open
$170.86
50D MA
$212.74
Beta
0.88
Avg. Volume
1.08M
EPS (Annual)
$3.48
P/B
7.78
Rev/Employee
$501,500.00
$20,718.68
Loading...
Loading...
News
all
press releases
Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced the publication of its 2025 Sustainability Report, showcasing progress across its operations, products, people, and community. The...
Business Wire·19h ago
News Placeholder
More News
News Placeholder
Strs Ohio Boosts Stake in Insulet Corporation $PODD
Strs Ohio grew its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 36.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,680 shares of the medical instruments supplier's stock after buying...
MarketBeat·20h ago
News Placeholder
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of +25.93% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
Zacks·2d ago
News Placeholder
Insulet (PODD) Upgraded to Buy: Here's Why
Insulet (PODD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2d ago
News Placeholder
Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has enrolled the first participant in a pivotal...
Business Wire·2d ago
News Placeholder
PFA Pension Forsikringsaktieselskab Invests $10.91 Million in Insulet Corporation $PODD
PFA Pension Forsikringsaktieselskab purchased a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 37,992 shares of the medical instruments supplier's stock, va...
MarketBeat·2d ago
News Placeholder
Insulet Corporation $PODD Shares Bought by Danske Bank A S
Danske Bank A S grew its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 26.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,829 shares of the medical instruments supplier's s...
MarketBeat·2d ago
News Placeholder
Insulet Corporation $PODD Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA trimmed its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 14.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,137 shares of the medical instruments supplier's s...
MarketBeat·3d ago
News Placeholder
Insulet Corporation (NASDAQ:PODD) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Insulet Corporation (NASDAQ:PODD - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twenty-four ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five hav...
MarketBeat·3d ago
<
1
2
...
>

Latest PODD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.